Compare stocks

Kuros Biosciences AG is a biotechnology company focused on the development and commercialization of novel products for tissue repair and regeneration. The company's portfolio includes biomaterials and biologics aimed at enhancing bone healing in spinal, trauma, and cranio-maxillofacial surgeries. Headquartered in Schlieren, Switzerland, Kuros leverages its proprietary technologies to address unmet clinical needs in bone regeneration. The company's strategic positioning is strengthened by its focus on advanced biomaterial-based solutions, which differentiate its offering in the competitive regenerative medicine market.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.